Home・Akciju saraksts・Compugen Ltd

Compugen Ltd

Slēgts

2.48 1.22

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

2.46

Max

2.48

Galvenie mērījumi
By Trading Economics
Ienākumi	663K -7M
Pārdošana	426K 2.6M
P/E Sektora vidējais	6.526 56.432
EPS	-0.07
Peļņas marža	-269.254
Darbinieki	75
EBITDA	665K -7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+100.8% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 9. nov.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	9.8M 235M
Iepriekšējā atvēršanas cena	1.26
Iepriekšējā slēgšanas cena	2.48

Compugen Ltd Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 19. sept. 23:31 UTC

China's Loan Prime Rate announcement on September 21, 2026, is anticipated at 0.03%, amid global tightening trends influenced by rising inflation and Japan's recent rate hike to 1.25%.

2026. g. 19. sept. 23:31 UTC

China's Loan Prime Rate expected to hold at 3.50% on September 21, amid stable market sentiment and focus on international cooperation.

2026. g. 19. sept. 23:11 UTC

U.S. Mortgage Rates Hit 6.97% Amid Fed Rate Hike and Inflation Concerns, Signaling Potential Further Increases Ahead

2026. g. 19. sept. 23:11 UTC

Cautious Market Sentiment Ahead of Chicago Fed National Activity Index Release Amid Disappointing Economic Indicators

2026. g. 19. sept. 23:01 UTC

Avalanche is advancing sharply, continuing its strong upward trend, despite earlier pulling back from a session high, and trading well above its 20-day moving average.

2026. g. 19. sept. 23:01 UTC

Correlated Moves

XRP is advancing, continuing its upward trend since Friday's close, influenced by ongoing geopolitical tensions and recent interest rate hikes by major central banks.

2026. g. 19. sept. 22:51 UTC

Correlated Moves

The Russell 2000 Index is little changed in after-market hours, remaining near the lower end of its one-month range amid ongoing geopolitical tensions.

2026. g. 19. sept. 22:51 UTC

Correlated Moves

Macro News

The Dow Jones Index (US) is trading lower in after-market hours, reflecting minimal movement since Friday's close amid ongoing geopolitical tensions and a new Lockheed Martin contract.

2026. g. 19. sept. 22:51 UTC

The FTSE 100 Index is trading lower in after-market hours, positioned below its 20-day moving average amid ongoing geopolitical tensions affecting energy prices.

2026. g. 19. sept. 22:31 UTC

UK Consumer Confidence Index Forecasted at -16.0 Amid Cautious Market Sentiment and Rising Cost-of-Living Concerns

2026. g. 19. sept. 21:41 UTC

Australia's S&P Global Manufacturing PMI Flash set for September 22, with market expectations at neutral 50 amid cautious optimism and inflation concerns.

2026. g. 19. sept. 21:41 UTC

Australia's S&P Global Services PMI Flash release on September 22 faces cautious optimism amid mixed economic signals and global inflation concerns.

2026. g. 19. sept. 21:21 UTC

Brazil's Central Bank to Release COPOM Meeting Minutes Amid Global Interest Rate Shifts, Influencing Market Sentiment on SELIC Decisions

2026. g. 19. sept. 21:11 UTC

UK CBI Distributive Trades Forecasts -50.0 Amidst Recent Retail Sales Rebound, Indicating Mixed Consumer Sentiment Ahead of Q4

2026. g. 19. sept. 20:41 UTC

UK Manufacturing Sector Faces Caution Ahead of September 2026 CBI Industrial Trends Orders Forecasted at -35.0 Amid Mixed Economic Signals and Rising Cost Pressures.

2026. g. 19. sept. 20:41 UTC

API Crude Oil Stock Change Data Release on September 22, 2026, Amidst Volatile Market Influenced by Geopolitical Tensions and Mixed Investor Sentiment.

2026. g. 19. sept. 19:41 UTC

South Korea's Consumer Confidence Index set for release amid bearish market sentiment and rising interest rates, signaling potential consumer caution.

2026. g. 19. sept. 19:41 UTC

Correlated Moves

EUR/NZD is roughly flat since Friday's close, maintaining stability while the market is closed for the weekend and reflecting its position near the upper end of its one-month range.

2026. g. 19. sept. 19:41 UTC

Macro News

Volkswagen's fiscal outlook revision due to Porsche AG goodwill impairment is contributing to a decline in the IBEX 35 Index amid rising geopolitical tensions.

2026. g. 19. sept. 19:41 UTC

Macro News

The A50 Index (China) is modestly higher in after-market trading, amid rising geopolitical tensions and central bank interest rate hikes affecting risk assets.

2026. g. 19. sept. 19:11 UTC

Germany's Ifo Business Climate Index set for September 24 release amid cautious market sentiment and rising inflation expectations.

2026. g. 19. sept. 18:51 UTC

Investors Brace for Cautious S&P Global Composite PMI Flash Release Amid Rising Inflation Concerns in Euro Area

2026. g. 19. sept. 18:51 UTC

South Africa's Inflation Rate Set for Release Amid Cautious Market Sentiment Following July Decline to 4.3%.

2026. g. 19. sept. 18:51 UTC

Investors Brace for S&P Global Services PMI Flash Release Amid Rising Inflation Concerns and Mixed Economic Signals in Euro Area

2026. g. 19. sept. 18:51 UTC

Euro Area's S&P Global Manufacturing PMI Flash set for September 23, with forecasted growth amid rising inflation concerns and cautious investor sentiment.

2026. g. 19. sept. 18:51 UTC

South Africa's Inflation Rate Release on September 23, 2026 Sparks Caution Among Investors Amid Global Economic Pressures.

2026. g. 19. sept. 18:41 UTC

SNB Expected to Maintain 0% Interest Rate Amid Low Inflation and Strong Franc Ahead of September Decision

2026. g. 19. sept. 18:31 UTC

Spain's Balance of Trade report on September 22, 2026, raises concerns over systemic trade deficits amid rising inflation and cautious market sentiment.

2026. g. 19. sept. 18:21 UTC

Germany's S&P Global Services PMI Flash set for September 23, with cautious market sentiment amid rising inflation expectations and mixed economic indicators.

2026. g. 19. sept. 18:21 UTC

Germany's S&P Global Composite PMI Flash Release on September 23 Expected to Reflect Economic Challenges Amid Inflation and Geopolitical Uncertainty.

Salīdzinājums

Cenas izmaiņa

Compugen Ltd Prognoze

Cenas mērķis

By TipRanks

100.8% augšup

Prognoze 12 mēnešiem

Vidējais 5 USD 100.8%

Augstākais 6 USD

Zemākais 4 USD

Pamatojoties uz 2 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Compugen Ltd — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

2 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 2 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Compugen Ltd — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.